Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA1c and spikes of high glucose values in the third trimester

What Was Tested

Researchers studied Insulin Aspart and NPH Insulin (isophane) in this randomized controlled trial publication.

To analyse data from a randomised, controlled study of prandial insulin aspart versus human insulin, both with NPH insulin, in pregnant women with type 1 diabetes for potential factors predicting poor pregnancy outcomes.

RESEARCH DESIGN/METHOD: Post hoc analysis including 91 subjects randomised prior to pregnancy with known outcome in early pregnancy and 259 subjects randomised prior to pregnancy/during pregnancy of <10 weeks' gestation with known late-pregnancy outcomes.

Poor early-pregnancy outcomes included fetal loss <22 gestational weeks and/or congenital malformation (n=18).

Who Took Part

The study group was 91 subjects.

The age groups tagged for this paper are adults, women only.

How the Study Was Run

The design is described as randomized.

The subjects were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

What Was Measured

Topics PubMed links to this paper include Albuminuria, Blood Glucose, Congenital Abnormalities, Diabetes Mellitus, Type 1, Fetal Death, Food and Gestational Age.

What This Means in Plain Language

The paper is a randomized study of Insulin Aspart and NPH Insulin (isophane) in 91 subjects.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians), a journal based in England.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page.